Journey Medical's future hinges on Emrosi, a new formulation of minocycline for rosacea, showing superior efficacy. Read why ...

In Teva Branded Pharmaceutical Products R&D, Inc. v. Amneal Pharmaceuticals of New York, LLC, the Federal Circuit jumped on the bandwagon ...

In 2024, the Hatch-Waxman Act continued to play a critical role in the U.S. pharmaceutical landscape, driving the dynamics between ...

The driver, Kenneth Merideth, and passenger, Cody Maynard, are facing drug charges after the deputy found meth on Maynard and inside his book bag.

Companies say they are working to update their products to comply with the Food and Drug Administration's decision Wednesday to ban the artificial food dye Red 3, after the agency said it was ...

The decision allows ZYN nicotine pouches to be legally marketed in the U.S. to adults aged 21 and older, the FDA said in a news release on Thursday, Jan. 6. The small natural fiber pouches are ...

“Food safety is the number one priority for U.S. confectionery companies, and we will continue to follow and comply with FDA’s guidance and safety standards,” said Christopher ...

The US Food and Drug Administration (FDA) has announced that it has banned the use of synthetic food dye Red No.3 in food, drink, and ingested medicine products, after studies in rats linked it to ...

“Food safety is the number one priority for U.S. confectionery companies, and we will continue to follow and comply with FDA’s guidance and safety standards,” said Christopher Gindlesperger, senior ...

Jan. 14 (UPI) --The U.S. Food and Drug Administration hopes "front-of-package" labeling will better improve the American population's health, the FDA announced. "Food should be a vehicle for ...

The Food and Drug Administration has proposed moving nutrition labels to the front of most packaged foods, aiming to help consumers make healthier choices, officials said. The FDA officially unveiled ...

In the Notice Letter in January 2023, Teva stated that it intended to market a generic version of Firdapse before the expiration of multiple of Catalyst’s patents listed in the FDA Orange Book.